- Conditions
- Heart Failure
- Interventions
- LCZ696 (sacubitril/valsartan)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 794 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 66 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 1,384
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Autism Spectrum Disorder
- Interventions
- TB006
- Drug
- Lead sponsor
- Rossignol Medical Center
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Aliso Viejo, California
- Conditions
- Danon Disease
- Interventions
- RP-A501
- Biological
- Lead sponsor
- Rocket Pharmaceuticals Inc.
- Industry
- Eligibility
- 8 Years and older · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- La Jolla, California • Aurora, Colorado • Philadelphia, Pennsylvania
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- Nivolumab, Ipilimumab, Cobimetinib
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 19
- States / cities
- Muscle Shoals, Alabama • Aurora, Colorado • New Haven, Connecticut + 15 more
- Conditions
- Oxidative Stress
- Interventions
- Placebo low dose, N Acetyl cysteine, 600mg (low dose), Proimmune 200 (FT061452) 3000mg low dose, Placebo (high dose), N Acetyl cysteine, 1200mg (high dose), FT061452, 6000mg high dose
- Drug
- Lead sponsor
- Charles Drew University of Medicine and Science
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Advanced Cholangiocarcinoma, FGFR2 Fusion
- Interventions
- Pemigatinib, Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Tetraplegia, Asthma
- Interventions
- N-Nitro L-arginine-methylester (L-NAME)
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Rheumatoid Arthritis
- Interventions
- N/A (Observational Study)
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy, Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy
- Interventions
- Radiotherapy, Abraxane
- Radiation · Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • West Chester, Pennsylvania
- Conditions
- Relapsed Adult AML, Refractory AML
- Interventions
- Navitoclax Dose Level 1, Navitoclax Dose Level 0, Navitoclax Dose Level 2, Venetoclax Dose Level -1, Venetoclax Dose Levels 0 to 2, Cladribine, Cytarabine (Cladribine Low Dose Cytarabine Backbone), Cytarabine (CLAG-M Backbone), Mitoxantrone, Granulocyte Colony-Stimulating Factor
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Cancer of the Esophagus
- Interventions
- Panitumumab, Capecitabine, Oxaliplatin, Radiation Therapy (RT)
- Drug · Radiation
- Lead sponsor
- Brian Czito
- Other
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Liver Transplantation
- Interventions
- Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation
- Biological · Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Rochester, Minnesota
- Conditions
- Ovarian Cancer, Advanced Malignant Solid Tumor
- Interventions
- Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII, Aldesleukin
- Drug · Biological
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Asthma
- Interventions
- Omalizumab, Placebo, Fluticasone
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- busulfan, cyclophosphamide, cyclosporin-A, etoposide, methotrexate, rasburicase, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation, fludarabine, allopurinol
- Drug · Procedure · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Metabolic Syndrome
- Interventions
- intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
- Procedure · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 50 Years to 75 Years · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pemetrexed, Temsirolimus
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Solid Tumor
- Interventions
- Setidegrasib, Cetuximab, Leucovorin, Oxaliplatin, Fluorouracil, Irinotecan, Nanoparticle albumin-bound-paclitaxel, Gemcitabine, Docetaxel, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Liposomal Irinotecan
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- Duarte, California • Santa Monica, California • Denver, Colorado + 20 more
- Conditions
- Neuroblastoma
- Interventions
- Vorinostat, 131- I Metaiodobenzylguanidine, Peripheral Blood Stem Cell Infusion, Filgrastim
- Drug · Radiation · Procedure
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
- Conditions
- Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
- Interventions
- Labetuzumab Govitecan (LG)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 7
- States / cities
- Santa Monica, California • Aurora, Colorado • Newark, Delaware + 4 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 114
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more
- Conditions
- Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence
- Interventions
- Modified Atkins Diet, Absence epilepsy medications
- Other · Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pyridoxine Dependant Epilepsy
- Interventions
- Lysine Restricted Diet, Pyridoxine
- Dietary Supplement · Drug
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 3 Months to 3 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Seattle, Washington